HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $5 Price Target
10/5/2026
Impact: -75
Healthcare
HC Wainwright & Co. analyst Mitchell S. Kapoor has reiterated a 'Sell' rating on Sarepta Therapeutics (NASDAQ: SRPT) and maintained a price target of $5 for the stock.
AI summary, not financial advice
Share: